After 50 years, Sanofi is giving itself a bit of a branding make-over with a new logo and a restructuring of the France-based company’s corporate umbrella in support of its three-year-old “Play to Win” strategy.

Sanofi still expects the French drugmaker’s COVID-19 vaccine to complete a phase 3 trial in first-quarter 2022 and reported a rise in fourth-quarter 2021 sales and earnings on Feb. 4.

Merck & Co. expects the company’s 2022 sales to increase as much as 18 percent over 2021, mostly on sales of the new COVID-19 pill molnupiravir.

AbbVie reported the company’s fourth-quarter 2021 and full-year financial results on Feb. 2, with worldwide net reviews up 7.4% to $14.89 billion for the quarter. Total revenues for 2021 were $56 billion. The company’s anchor product remains Humira, which will begin to lose exclusivity in 2023.


Abbott Laboratories beat fourth-quarter 2021 profit and sales estimates, aided by robust sales of COVID-19 test kits and strong demand for the company’s diagnostics products, but forecast lower-than-expected COVID-19 testing sales in 2022 due to uncertainties around the future of the pandemic.

AstraZeneca reported Covid-19 vaccine sales of $1.05 billion for third-quarter 2021, with Vaxzevria contributing 1 percent to the company’s profit for the quarter.

Syneos Health, a fully integrated biopharmaceutical solutions organization, reported financial results for the three-month and nine-month periods ended September 30, 2021.

Amgen Chairman and Chief Executive Officer Robert Bradway anticipates the non-small cell lung cancer drug Lumakras will become a cornerstone medicine as the company aims to develop multiple medications for targets long thought to be undruggable.

AbbVie Inc. on Oct. 29 raised the company’s 2021 adjusted profit forecast for the third time this year after a stellar performance by newer medicines helped the U.S. drugmaker beat Wall Street estimates for third-quarter profit and revenue.

Teva Pharmaceutical Industries Ltd. inked a deal to license and develop two of MODAG GmbH’s compounds in neurodegenerative disease.